DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-12.43%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$367M
AUM Growth
+$367M
(-4.4%)
Cap. Flow
+$50M
Cap. Flow
% of AUM
13.63%
Top 10 Holdings %
Top 10 Hldgs %
47.4%
Holding
97
New
3
Increased
39
Reduced
15
Closed
7
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$25.5M |
| 2 |
Ascendis Pharma
ASND
|
$10.1M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$4.74M |
| 4 |
DexCom
DXCM
|
$4.06M |
| 5 |
Adicet Bio
ACET
|
$3.21M |
Top Sells
| 1 |
RGLS
Regulus Therapeutics
RGLS
|
$10.4M |
| 2 |
Biomea Fusion
BMEA
|
$2.96M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$2.53M |
| 4 |
Athira Pharma
ATHA
|
$2.17M |
| 5 |
Cogent Biosciences
COGT
|
$1.67M |
Sector Composition
| 1 | Healthcare | 80.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $45.5M | 12.41% | 613,000 +343,500 | +127% | +$25.5M |
|
2
Stereotaxis
STXS
$261M
| $25.2M | 6.86% | 13,680,554 | – | – |
|
|
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $16M | 4.37% | 110,100 +32,500 | +42% | +$4.74M |
|
|
4
Adicet Bio
ACET
$59.9M
| $13.7M | 3.72% | 935,766 +219,894 | +31% | +$3.21M |
|
5
Fate Therapeutics
FATE
$120M
| $13.7M | 3.72% | 550,940 +50,010 | +10% | +$1.24M |
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $13.3M | 3.64% | 438,623 +58,460 | +15% | +$1.78M |
|
|
BPMC
7
DELISTED
Blueprint Medicines
BPMC
| $13.2M | 3.6% | 261,280 +15,000 | +6% | +$758K |
|
|
8
Ascendis Pharma
ASND
$11.8B
| $12.9M | 3.53% | 139,212 +108,600 | +355% | +$10.1M |
|
9
iShares Biotechnology ETF
IBB
$5.6B
| $12.1M | 3.29% | 102,500 | – | – |
|
10
Cytokinetics
CYTK
$4.23B
| $8.31M | 2.26% | 211,495 | – | – |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $8.06M | 2.2% | 82,655 -1,000 | -1% | -$97.5K |
|
|
KRTX
12
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $7.85M | 2.14% | 62,053 -20,000 | -24% | -$2.53M |
|
13
IDEAYA Biosciences
IDYA
$2.15B
| $7.57M | 2.06% | 548,561 +58,500 | +12% | +$807K |
|
14
Nurix Therapeutics
NRIX
$714M
| $7.18M | 1.96% | 566,695 +23,351 | +4% | +$296K |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.14M | 1.95% | 370,987 -1,000 | -0.3% | -$19.2K |
|
16
Merus
MRUS
$4.98B
| $5.95M | 1.62% | 262,891 +27,902 | +12% | +$632K |
|
17
Revolution Medicines
RVMD
$7.1B
| $5.84M | 1.59% | 299,785 +67,684 | +29% | +$1.32M |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $5.82M | 1.59% | 180,306 | – | – |
|
19
Alector
ALEC
$238M
| $5.61M | 1.53% | 552,438 +259,691 | +89% | +$2.64M |
|
20
Edgewise Therapeutics
EWTX
$1.51B
| $5.54M | 1.51% | 695,959 +339,209 | +95% | +$2.7M |
|
|
21
DexCom
DXCM
$29.5B
| $5.41M | 1.47% | 72,552 +54,414 | +300% | +$4.06M |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.34M | 1.46% | 79,600 +36,900 | +86% | +$2.48M |
|
|
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
| $5.27M | 1.44% | 1,787,569 +95,000 | +6% | +$280K |
|
24
Arcus Biosciences
RCUS
$1.13B
| $4.76M | 1.3% | 187,717 +42,500 | +29% | +$1.08M |
|
|
NTUS
25
DELISTED
Natus Medical Inc
NTUS
| $4.71M | 1.28% | 143,600 -47,035 | -25% | -$1.54M |
|